Transcatheter Valve Therapies (TVT)

Transcatheter Cardiovascular Therapeutics (TCT)

Transcatheter Cardiovascular Therapeutics (TCT)

Researchers with the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, have collaborated with physicians and medical geneticists around the world to create the Atlas of Human Malformation Syndromes in Diverse Populations.

San Diago Cardiovascular Interventions

The 2016 San Diego Cardiovascular Interventions Course will focus on disseminating the knowledge and evidence-based data regarding new therapies and techniques for the treatment of high-risk patients with complex cardiovascular disease. These new therapeutic modalities include the use of robotic technology for enhancing precision and physician safety. Additionally, new approaches toward patients with chronic total occlusions, left main and multivessel disease, left ventricular dysfunction requiring hemodynamic support, and severe valvular heart disease will be presented.

National Annual Conference of Indian Association of Clinical Cardiologists

The 7th annual National Annual Conference of Indian Association of Clinical Cardiologists (IACCCON) 2016is scheduled to be held at Ranchi, India from Sept. 23-25, 2016. The venue of this event is Hotel Radisson Blu, Ranchi.

May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May 4-6, SCAI will begin efforts to collect real data on the impact of radiation-induced cataracts amongst the cardiovascular cath lab team.

Through the IC-CATARACT initiative led by Manos Brilakis, M.D., Ph.D., FSCAI, and his team of researchers from VA North Texas Healthcare System and UT Southwestern Medical Center, will offer free eye exams at the SCAI meeting in the IC-CATARACT suite in the exhibit hall. 

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease.

April 29, 2016 — AtriCure Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now